The CJC-1295 research record, read closely

What the research is and is not

The CJC-1295 human evidence base is unusually small. One Phase 1 pharmacology paper from 2006 anchors almost everything the published literature can say with confidence about how the compound behaves in people. A companion pulsatility analysis draws on the same cohort. A proteomics study followed up with stored serum samples from the same group. That is essentially the human clinical record.

A Phase 2 trial in HIV-related visceral fat was terminated in 2006 — its primary efficacy endpoints were never published. No Phase 3 trial has ever been run. The rest of the post-2006 literature is mechanistic, analytical, or regulatory: receptor pharmacology, anti-doping detection methods, FDA advisory committee briefings, WADA prohibited-list entries.

Reading this page closely means reading a short, technically interesting record — not a thick clinical dossier. What it shows is clear. What it does not show — long-term safety, confirmed benefit in healthy adults, efficacy for any approved indication — is also clear. Both are worth reading carefully.

Mechanism at the GHRH receptor

CJC-1295 binds the growth hormone-releasing hormone receptor (GHRHR), a class-B G-protein-coupled receptor expressed on anterior pituitary somatotrophs — the cells that store and release growth hormone. Receptor binding activates a Gs/adenylyl cyclase/cAMP/PKA signaling cascade, which drives transcription of the growth hormone gene and triggers vesicular release of stored GH ^[1][3].

The four substitutions in the GRF(1-29) backbone — D-alanine at position 2, glutamine at 8, alanine at 15, leucine at 27 — are chosen to do two things at once. They preserve the α-helical conformation the receptor needs to recognize, and they sterically block the enzyme dipeptidyl peptidase-4 (DPP-4) from clipping the peptide at its N-terminus ^[1]. Native GHRH is cleaved by DPP-4 within minutes; the modified backbone resists that cleavage and survives in plasma for about thirty minutes without DAC. With DAC — the maleimide handle on the C-terminal lysine — the peptide covalently couples to serum albumin's free thiol at Cys34 after subcutaneous injection, and the conjugate then circulates with the carrier protein for days ^[1][2].

The effect at the somatotroph is GH release. The effect at the liver, several hours later, is increased IGF-1 production via the GH-receptor JAK2/STAT5 pathway ^[8]. The two together — pituitary GH and hepatic IGF-1 — are what most CJC-1295 studies measure.

The Teichman 2006 Phase 1 study

The largest published human dataset on CJC-1295 is a Phase 1 PK/PD study by Teichman and colleagues in healthy adults ^[2]. Single subcutaneous doses of 30, 60, 125, or 250 μg/kg produced dose-dependent increases in mean plasma GH of two- to ten-fold lasting at least six days, and dose-dependent increases in mean IGF-1 of 1.5- to 3-fold lasting nine to eleven days. In multi-dose cohorts given weekly or biweekly injections at 60 to 125 μg/kg, IGF-1 elevation was sustained through twenty-eight days without obvious tachyphylaxis ^[2].

Adverse events were predominantly mild and local — injection-site reactions, headache, and transient flushing. Mean plasma half-life of the DAC conjugate was estimated at 5.8 to 8.1 days, with the upper bound approaching the half-life of serum albumin itself (about nineteen to twenty-one days) and the lower bound reflecting receptor desensitization and pharmacodynamic decoupling ^[2].

This is the cleanest human PK dataset on the compound. It is also, twenty years later, the only Phase 1 paper of its kind on CJC-1295. Everything subsequent has been mechanism work, analytical method development, or regulatory review.

Pulsatile GH architecture is preserved

A companion analysis of the Teichman cohort focused on whether continuous CJC-1295 exposure flattens the natural pulsatile rhythm of growth hormone release ^[3]. Under continuous stimulation by exogenous recombinant GH, the pituitary's own pulsatile output is suppressed; the question was whether a long-acting GHRH analog would have the same effect.

Ionescu and Frohman found that it did not. Single subcutaneous doses raised basal (trough) GH approximately 7.5-fold while preserving pulse frequency and amplitude. Mean GH ran about 46 percent above baseline, with the elevation distributed across continued pulsatile bursts rather than appearing as a tonic flood ^[3]. This is the pharmacological feature that distinguishes CJC-1295 mechanistically from exogenous recombinant GH replacement — the somatotrophs continue to do their own work; the GHRH input is amplified.

Growth restoration in GHRH-knockout mice

The most directly mechanistic in vivo work is a mouse study by Alba and colleagues in animals genetically deficient in GHRH ^[4]. GHRH-knockout mice are growth-impaired by adulthood; the question was whether daily exogenous CJC-1295 could rescue normal growth.

At 2 μg subcutaneous per injection once daily for five weeks — about 80 μg/kg in a 25-gram mouse — body length, body weight, and lean composition returned to wild-type ranges. Dosing at 48-hour and 72-hour intervals produced partial restoration. Histology showed increased anterior-pituitary somatotroph proliferation and elevated GH-mRNA, indicating CJC-1295 supports not only acute GH release but also longer-term trophic effects on the cell population that makes GH ^[4].

Anti-doping analytical work

A surprising amount of the post-2006 literature is analytical — methods developed to detect CJC-1295 exposure in athletes and racehorses, since the compound is on the WADA prohibited list and has been found in seized illicit pharmaceutical preparations ^[5][6][7].

Timms and colleagues developed monoclonal antibodies against CJC-1295 and used them in an immuno-polymerase chain reaction (I-PCR) assay capable of detecting the CJC-1295-albumin conjugate in equine plasma down to 0.8 pg/mL ^[5]. A screening threshold of 50 pg/mL was set to discriminate exogenous CJC-1295 from native equine GHRH. A follow-up paper used immunoaffinity capture followed by tryptic digestion and tandem mass spectrometry to confirm CJC-1295 identity at 180 pg/mL in 1 mL of equine plasma ^[6]. The analytical problem the immunoaffinity step solves is that CJC-1295 covalently bound to albumin cannot be detected by conventional intact-peptide mass spectrometry — the antibody capture concentrates the bound conjugate before tryptic release of diagnostic fragments.

Earlier work by Henninge and colleagues used LC-HRMS/MS to sequence a peptide preparation seized by an anti-doping laboratory and confirmed its identity as CJC-1295 ^[7] — an early demonstration that CJC-1295 had moved from clinical-trial supply into illicit distribution channels. These methods are now in routine use by accredited anti-doping laboratories.

The terminated Phase 2 program

The largest CJC-1295 human exposure on the public record is NCT00267527, a randomized double-blind placebo-controlled trial sponsored by ConjuChem in adults with HIV-associated visceral adiposity (n=192, weekly subcutaneous dosing) ^[9]. The trial was terminated in October 2006 after a participant died of an acute coronary event approximately two hours after the eleventh weekly dose. Independent review attributed the event to pre-existing undiagnosed coronary artery disease and judged it not study-drug related, but the program was not restarted, and primary efficacy endpoints have never been published in the peer-reviewed literature.

The indication ConjuChem was pursuing — visceral-fat reduction in HIV-associated lipodystrophy — was eventually approved for a structurally related GHRH analog called tesamorelin, which produced a 15 to 20 percent reduction in visceral adipose tissue over 26 weeks of daily subcutaneous dosing in a randomized trial in HIV-infected adults ^[11]. Tesamorelin is the only FDA-approved member of the GHRH-analog class, and the clearest available pharmacological reference point for what CJC-1295's Phase 2 program might have shown had it been completed.

Regulatory and pharmacovigilance signals (2024–2026)

The FDA's Pharmacy Compounding Advisory Committee reviewed CJC-1295 twice in 2024 — first in October and again in a December follow-up meeting ^[14][20]. The October briefing cited immunogenicity risk from peptide aggregates and impurities, with the injectable subcutaneous route considered a particularly high-risk presentation. Nonclinical findings cited included reduced hemoglobin, elevated cholesterol, injection-site inflammation and necrosis, and pituitary DNA-damage signals; clinical adverse-event signals cited included increased heart rate and systemic vasodilatory reactions on top of the milder injection-site reactions, headache, and flushing reported in Teichman 2006. The committee did not recommend inclusion of CJC-1295 on the 503A bulk drug substances list ^[14].

In July 2025, FDA issued a Class II recall on a specific brand of compounded CJC-1295 injectable for lack of assurance of sterility ^[16] — a concrete real-world quality-control data point illustrating the immunogenicity and impurity concerns articulated at PCAC. In April 2026, FDA removed CJC-1295 from Category 2 of the 503A bulk drug substances list after the nomination was withdrawn; the substance was not moved to Category 1, leaving it in a regulatory gray zone with no permitted routine compounding pathway ^[15]. CJC-1295 has remained on the WADA prohibited list (Section S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics) at all times since the analytical literature first established detection methods ^[17].